These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37594219)

  • 61. Less Than One-third of Hospitals Provide Compliant Price Transparency Information for Total Joint Arthroplasty Procedures.
    Burkhart RJ; Hecht CJ; Acuña AJ; Kamath AF
    Clin Orthop Relat Res; 2022 Dec; 480(12):2316-2326. PubMed ID: 35901439
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prices for Physicians' Services in Medicare Advantage and Commercial Plans.
    Pelech DM
    Med Care Res Rev; 2020 Jun; 77(3):236-248. PubMed ID: 29936886
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Negotiated Rates for Surgical Cancer Care in the Era of Price Transparency-Prices Reflect Market Competition.
    Rochlin DH; Rizk NM; Matros E; Wagner TH; Sheckter CC
    Ann Surg; 2024 Mar; 279(3):385-391. PubMed ID: 37678179
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reference Pricing with Endogenous or Exogenous Payment Limits: Impacts on Insurer and Consumer Spending.
    Brown TT; Robinson JC
    Health Econ; 2016 Jun; 25(6):740-9. PubMed ID: 25903495
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate.
    Brant A; Lewicki P; Rhodes S; Arenas-Gallo C; Strasser MO; Zhu A; Ponsky L; Shoag JE
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):252-256. PubMed ID: 36717642
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Factors affecting bargaining outcomes between pharmacies and insurers.
    Brooks JM; Doucette W; Sorofman B
    Health Serv Res; 1999 Apr; 34(1 Pt 2):439-51. PubMed ID: 10199687
    [TBL] [Abstract][Full Text] [Related]  

  • 67. THE PRICE AIN'T RIGHT? HOSPITAL PRICES AND HEALTH SPENDING ON THE PRIVATELY INSURED.
    Cooper Z; Craig SV; Gaynor M; Van Reenen J
    Q J Econ; 2019 Feb; 134(1):51-107. PubMed ID: 32981974
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The relationship between community social risk factors and regional hospital-reported cash, negotiated, and chargemaster prices for 14 common services.
    Chang E; Psek W
    BMC Health Serv Res; 2024 Mar; 24(1):299. PubMed ID: 38448915
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Offering A Price Transparency Tool Did Not Reduce Overall Spending Among California Public Employees And Retirees.
    Desai S; Hatfield LA; Hicks AL; Sinaiko AD; Chernew ME; Cowling D; Gautam S; Wu SJ; Mehrotra A
    Health Aff (Millwood); 2017 Aug; 36(8):1401-1407. PubMed ID: 28784732
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluating the Impact of Health Insurance Industry Consolidation: Learning from Experience.
    Dafny LS
    Issue Brief (Commonw Fund); 2015 Nov; 33():1-11. PubMed ID: 26634241
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Price setting in the Brazilian private health insurance sector.
    Andrade MV; Marinho C; Nunes L; Colares F
    Int J Health Econ Manag; 2024 Mar; 24(1):57-80. PubMed ID: 37691041
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Commercial Price Variation for Breast Reconstruction in the Era of Price Transparency.
    Rochlin DH; Rizk NM; Matros E; Wagner TH; Sheckter CC
    JAMA Surg; 2023 Feb; 158(2):152-160. PubMed ID: 36515928
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Understanding differences between high- and low-price hospitals: implications for efforts to rein in costs.
    White C; Reschovsky JD; Bond AM
    Health Aff (Millwood); 2014 Feb; 33(2):324-31. PubMed ID: 24476706
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Market competition and price of disease management programmes: an observational study.
    van Dijk CE; Venema B; de Jong JD; de Bakker DH
    BMC Health Serv Res; 2014 Oct; 14():510. PubMed ID: 25359224
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Why do narrow network plans cost less?
    Liebman E; Panhans MT
    Health Econ; 2021 Sep; 30(10):2437-2451. PubMed ID: 34263506
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance.
    Xiao R; Ross JS; Gross CP; Dusetzina SB; McWilliams JM; Sethi RKV; Rathi VK
    JAMA Intern Med; 2022 Jun; 182(6):603-611. PubMed ID: 35435948
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pricing behaviour of nonprofit insurers in a weakly competitive social health insurance market.
    Douven RC; Schut FT
    J Health Econ; 2011 Mar; 30(2):439-49. PubMed ID: 21295365
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Is the medical loss ratio a good target measure for regulation in the individual market for health insurance?
    Karaca-Mandic P; Abraham JM; Simon K
    Health Econ; 2015 Jan; 24(1):55-74. PubMed ID: 24123608
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Does competition improve hospital performance: a DEA based evaluation from the Netherlands.
    Dohmen P; van Ineveld M; Markus A; van der Hagen L; van de Klundert J
    Eur J Health Econ; 2023 Aug; 24(6):999-1017. PubMed ID: 36192512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.